Soybean Oil
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
SOYBEAN OIL: From No Established Indication to Amenorrhea (Disease)
One-Sentence Summary
Soybean oil is not registered as a marketed drug in Taiwan and has no documented original therapeutic indication; it is primarily known as a lipid emulsion/excipient component (e.g., in parenteral nutrition or drug carriers). The TxGNN model predicts it may be effective for Amenorrhea, but this prediction is currently supported by 0 clinical trials and 0 publications.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no approved indication on record) |
| Predicted New Indication | Amenorrhea (disease) |
| TxGNN Prediction Score | 99.61% |
| Evidence Level | L5 |
| US Market Status | 未上市 (Not marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, soybean oil is primarily used as a lipid component in parenteral nutrition formulations and as an excipient/carrier in various drug products, rather than as an active pharmacological agent with a defined therapeutic indication.
There is no documented original indication to compare against amenorrhea, and no known endocrine or reproductive-axis pharmacology has been established for soybean oil. The predicted link between soybean oil and amenorrhea lacks biological plausibility based on currently available data.
The TxGNN score of 99.61% reflects graph-based node proximity within the knowledge graph rather than an established causal or mechanistic relationship. Given the absence of any supporting clinical trials, literature, or known MOA, this prediction should be treated as a low-confidence signal that likely reflects a false-positive association from graph topology rather than a genuine pharmacological hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
US Market Information
Soybean oil is not currently marketed in Taiwan (0 NDAs/licenses on record); no product information is available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is supported only by a TxGNN model score (L5, no clinical or literature evidence), and lacks any known mechanism of action linking soybean oil to amenorrhea. Combined with the absence of Taiwan market authorization and blocking data gaps in safety information, there is insufficient basis to advance this candidate.
To proceed, the following is needed:
- TFDA package insert warnings/contraindications (currently a Blocking data gap)
- Detailed mechanism of action (MOA) data from DrugBank or primary literature
- At least preclinical or mechanistic evidence linking soybean oil (or its metabolites) to reproductive/endocrine pathways
- Reassessment of TxGNN prediction validity given the complete absence of supporting real-world evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.